Valneva Reports Flat 2025 Revenue, Eyes Transformative Lyme Disease Data in 2026
Event summary
- Valneva reported €174.7 million in total revenue for 2025, in line with guidance, with product sales at €157.9 million.
- Year-end cash position stood at €109.7 million, down from €168.3 million in 2024, following debt refinancing.
- 2026 revenue guidance set at €155-170 million, with product sales expected between €145-160 million.
- Phase 3 data for Lyme disease vaccine candidate VLA15 anticipated in the first half of 2026.
- CEO Thomas Lingelbach's contract renewed for a further three-year term.
The big picture
Valneva's 2025 results reflect resilience amid geopolitical pressures and the wind-down of third-party sales. The company's strategic focus on Lyme disease and Shigella vaccines positions it in high-unmet medical needs, though execution risks remain. The CEO's contract renewal ensures leadership continuity as Valneva navigates a potentially transformative year in 2026.
What we're watching
- Regulatory Milestones
- The pace at which Phase 3 data for VLA15 could enable regulatory submissions and commercialization by Pfizer.
- Pipeline Progress
- Whether Valneva can sustain R&D momentum with Phase 2 data for the Shigella vaccine candidate S4V2 expected in 2026.
- Financial Discipline
- How Valneva manages cash burn while maintaining strategic R&D investments amid lower product sales guidance.
Related topics